News

Stories

See all

2021 Updates: Lilly's Global COVID-19 Response

View Story

Supporting United Way to Meet New Challenges

View Story

Racial Justice Initiative: Confronting Racial Inequities Head On

View Story

How Digital and Remote Health Can Help Next-Generation VBAs

View Story

Meet the Women Behind Our Cancer Research

View Story

Christalyn Rhodes, Ph.D.

Christalyn Rhodes: Living Her Purpose, Our Purpose

View Story


Press Releases

See all

EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

March 5, 2021

Tags |  Product

CHMP has completed a review of available data for both antibodies for the treatment of confirmed COVID-19 CHMP scientific opinion supports national decision-making within European Union (EU) member states on the use of the antibodies during a public health emergency before a formal marketing




Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet

March 5, 2021

Tags |  Product

INDIANAPOLIS , March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clinical trial in




Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes

March 4, 2021

Tags |  Product

Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg At the lowest dose of tirzepatide (5 mg), participants achieved A1C




Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

March 3, 2021

Tags |  Product

- Baricitinib met primary endpoint of hair regrowth across both dosing regimens - There are currently no FDA-approved treatments for AA INDIANAPOLIS , March 3, 2021 /PRNewswire/ --  Eli Lilly and Company  (NYSE: LLY) and  Incyte  (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a